Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
Key Highlights
- ➤Oculis will present new ACUITY biomarker analyses at the ACTRIMS-ECTRIMS meeting.
- ➤Privosegtor data evaluate plasma NfL and GFAP in acute optic neuritis.
- ➤Privosegtor received FDA Breakthrough Therapy and EMA PRIME designations.
- ➤PIONEER-1 is enrolling acute-onset optic neuritis patients across a broad population.
- ➤Oculis plans to file an IND for Privosegtor in acute MS relapses.
Expert Statements
Riad Sherif, Chief Executive Officer of Oculis
“Optic neuritis and demyelinating relapses represent a high-stakes clinical race against permanent neuro-axonal loss and irreversible functional deficits such as visual impairments”
Riad Sherif, Chief Executive Officer of Oculis
“With no approved neuroprotective therapies currently available to protect retinal ganglion cells and their axons, which transmit visual signals from the eye to the brain, deep translational analyses are vital to advancing care.”
Riad Sherif, Chief Executive Officer of Oculis
“At ECTRIMS, Professor Céline Louapre will present objective plasma biomarker readouts from the Phase 2 ACUITY trial, offering key insights into the biological pathways of optic neuritis and the neuroprotective potential of Privosegtor.”
Riad Sherif, Chief Executive Officer of Oculis
“We invite the international clinical and scientific community to join us for this late-breaking presentation as we work to advance the next frontier of neuroprotection.”
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation
ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announced that new biomarker data from the Phase 2 ACUITY trial of Privosegtor will be featured in a late-breaking session at the 10(th) Joint ACTRIMS-ECTRIMS Meeting (MSToronto 2026), on October 21-23, 2026, in Toronto, Canada.
Get started
Create a free account to read the full story.